Biomarkers in cancer最新文献_第6页

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade. PD-1/PD-L1阻断的人类癌症免疫治疗

Biomarkers in cancer Pub Date : 2015-09-20 eCollection Date: 2015-01-01 DOI: 10.4137/BIC.S29325

Peilin Zheng, Zhiguang Zhou

引用次数: 59

Tissue Factor-Factor VII Complex As a Key Regulator of Ovarian Cancer Phenotypes. 组织因子-因子VII复合物作为卵巢癌表型的关键调节因子。

Biomarkers in cancer Pub Date : 2015-09-06 eCollection Date: 2015-01-01 DOI: 10.4137/BIC.S29318

Shiro Koizume, Yohei Miyagi

引用次数: 14

BRAF Mutation in Colorectal Cancer: An Update. 结直肠癌中的BRAF突变:最新进展

Biomarkers in cancer Pub Date : 2015-09-06 eCollection Date: 2015-01-01 DOI: 10.4137/BIC.S25248

David Barras

引用次数: 124

Histopathological Features of Non-Neoplastic Breast Parenchyma Do Not Predict BRCA Mutation Status of Patients with Invasive Breast Cancer. 非肿瘤性乳腺实质的组织病理学特征无法预测浸润性乳腺癌患者的 BRCA 基因突变状态。

Biomarkers in cancer Pub Date : 2015-08-18 eCollection Date: 2015-01-01 DOI: 10.4137/BIC.S29716

Soley Bayraktar, Hongming Qiu, Diane Liu, Yu Shen, Angelica M Gutierrez-Barrera, Banu K Arun, Aysegul A Sahin

{"title":"Histopathological Features of Non-Neoplastic Breast Parenchyma Do Not Predict BRCA Mutation Status of Patients with Invasive Breast Cancer.","authors":"Soley Bayraktar, Hongming Qiu, Diane Liu, Yu Shen, Angelica M Gutierrez-Barrera, Banu K Arun, Aysegul A Sahin","doi":"10.4137/BIC.S29716","DOIUrl":"10.4137/BIC.S29716","url":null,"abstract":"Background: Several studies have evaluated histologic features of non-neoplastic breast parenchyma in patients with BRCA1/2 mutations, but the results are conflicting. The limited data suggest a much higher prevalence of high-risk precursor lesions in BRCA carriers. Therefore, we designed this study to compare the clinicopathological characteristics of peritumoral benign breast tissue in patients with and without deleterious BRCA mutations.Methods: Women with breast cancer (BC) who were referred for genetic counseling and underwent BRCA genetic testing in 2010 and 2011 were included in the study.Results: Of the six benign histological features analyzed in this study, only stromal fibrosis grade 2/3 was found to be statistically different, with more BRCA noncarriers having stromal fibrosis grade 2/3 than BRCA1/2 carriers (P = 0.04).Conclusion: There is no significant association between mutation risk and the presence of benign histologic features of peritumoral breast parenchyma.","PeriodicalId":72377,"journal":{"name":"Biomarkers in cancer","volume":"7 ","pages":"39-49"},"PeriodicalIF":0.0,"publicationDate":"2015-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4541461/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33967894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Infrequent Expression of the Cancer-Testis Antigen, PASD1, in Ovarian Cancer. 癌睾丸抗原pas1在卵巢癌中的罕见表达

Biomarkers in cancer Pub Date : 2015-08-16 eCollection Date: 2015-01-01 DOI: 10.4137/BIC.S28378

Ghazala Khan, Suzanne E Brooks, Ken I Mills, Barbara-Ann Guinn

{"title":"Infrequent Expression of the Cancer-Testis Antigen, PASD1, in Ovarian Cancer.","authors":"Ghazala Khan, Suzanne E Brooks, Ken I Mills, Barbara-Ann Guinn","doi":"10.4137/BIC.S28378","DOIUrl":"https://doi.org/10.4137/BIC.S28378","url":null,"abstract":"Ovarian cancer is very treatable in the early stages of disease; however, it is usually detected in the later stages, at which time, treatment is no longer as effective. If discovered early (Stage I), there is a 90% chance of five-year survival. Therefore, it is imperative that early-stage biomarkers are identified to enhance the early detection of ovarian cancer. Cancer-testis antigens (CTAs), such as Per ARNT SIM (PAS) domain containing 1 (PASD1), are unique in that their expression is restricted to immunologically restricted sites, such as the testis and placenta, which do not express MHC class I, and cancer, making them ideally positioned to act as targets for immunotherapy as well as potential biomarkers for cancer detection where expressed. We examined the expression of PASD1a and b in a number of cell lines, as well as eight healthy ovary samples, eight normal adjacent ovarian tissues, and 191 ovarian cancer tissues, which were predominantly stage I (n = 164) and stage II (n = 14) disease. We found that despite the positive staining of skin cancer, only one stage Ic ovarian cancer patient tissue expressed PASD1a and b at detectable levels. This may reflect the predominantly stage I ovarian cancer samples examined. To examine the restriction of PASD1 expression, we examined endometrial tissue arrays and found no expression in 30 malignant tumor tissues, 23 cases of hyperplasia, or 16 normal endometrial tissues. Our study suggests that the search for a single cancer-testes antigen/biomarker that can detect early ovarian cancer must continue. ","PeriodicalId":72377,"journal":{"name":"Biomarkers in cancer","volume":"7 ","pages":"31-8"},"PeriodicalIF":0.0,"publicationDate":"2015-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/BIC.S28378","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33967892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Interleukin 1β-A Potential Salivary Biomarker for Cancer Progression? 白细胞介素1β-潜在的癌症进展的唾液生物标志物?

Biomarkers in cancer Pub Date : 2015-07-08 eCollection Date: 2015-01-01 DOI: 10.4137/BIC.S25375

Adi Idris, Nur B Ghazali, David Koh

引用次数: 28

Elevated Expression of the Testis-specific Gene WBP2NL in Breast Cancer. 睾丸特异性基因WBP2NL在乳腺癌中的表达升高

Biomarkers in cancer Pub Date : 2015-06-29 eCollection Date: 2015-01-01 DOI: 10.4137/BIC.S19079

Seyedmehdi Nourashrafeddin, Mehdi Dianatpour, Mahmoud Aarabi, Maryam Beigom Mobasheri, Golnesa Kazemi-Oula, Mohammad Hossein Modarressi

{"title":"Elevated Expression of the Testis-specific Gene WBP2NL in Breast Cancer.","authors":"Seyedmehdi Nourashrafeddin, Mehdi Dianatpour, Mahmoud Aarabi, Maryam Beigom Mobasheri, Golnesa Kazemi-Oula, Mohammad Hossein Modarressi","doi":"10.4137/BIC.S19079","DOIUrl":"https://doi.org/10.4137/BIC.S19079","url":null,"abstract":"Breast cancer is one of the most common causes of cancer death in women; therefore, the study of molecular aspects of breast cancer for finding new biomarkers is important. Recent studies have shown that WW domain-binding protein 2 (WBP2) is important for the oncogenic property of breast cancer. WWP2 N-terminal-like (WBP2NL) is a testis-specific signaling protein that induces meiotic resumption and oocyte activation events. Our previous study revealed that WBP2NL gene expression is elevated in actively dividing cells and it might be associated with cellular proliferation and tumorigenic process. However, the clinical relevance and importance of WBP2NL gene in cancer has not been understood yet. Therefore, we were interested in analyzing the expression of WBP2NL gene in human breast cancer tissues and breast cancer cell lines, for the first time. We used reverse transcription-polymerase chain reaction (RT-PCR) and semi-nested RT-PCR to evaluate the expression of WBP2NL in malignant breast cancer and adjacent noncancerous tissue (ANCT) samples, as well as MCF-7 and MDA-MB-231 cell lines. The WBP2NL gene was expressed in 45 out of 50 (90%) breast cancer tissues and overexpressed in the MDA-MB-231 cell line. We suggest that WBP2NL may play roles in breast cancer activation maybe through binding to a group I WW domain protein. The elevated expression of WBP2NL gene in breast cancer and MDA-MB-231 cell line leads us to suggest that WBP2NL might be considered as a novel prognostic factor for early diagnosis of breast cancer. ","PeriodicalId":72377,"journal":{"name":"Biomarkers in cancer","volume":"7 ","pages":"19-24"},"PeriodicalIF":0.0,"publicationDate":"2015-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/BIC.S19079","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33992092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

Biomarkers in cancer Pub Date : 2015-06-08 eCollection Date: 2015-01-01 DOI: 10.4137/BIC.S23088

Lauren C Houghton, Michael N Pollak, Yuzhen Tao, Ying Gang Tu, Amanda Black, Gary Bradwin, Robert N Hoover, Rebecca Troisi

{"title":"Similarity of Serum and Plasma Insulin-like Growth Factor Concentrations.","authors":"Lauren C Houghton, Michael N Pollak, Yuzhen Tao, Ying Gang Tu, Amanda Black, Gary Bradwin, Robert N Hoover, Rebecca Troisi","doi":"10.4137/BIC.S23088","DOIUrl":"https://doi.org/10.4137/BIC.S23088","url":null,"abstract":"Background: Insulin-like growth factors (IGFs) are implicated in many normal physiological processes and pathological states, including cancer. For large consortia projects, it may be necessary to make comparisons among studies with different specimens that were not collected specifically to optimize the measurement of IGFs.Objective: This study aimed to compare IGFs in matched serum and plasma samples.Methods: We measured IGF-I, IGF-II, insulin-like growth factor-binding protein (IGFBP)-3, C-peptide, and leptin in serum and ethylenediaminetetraacetic-containing-plasma samples obtained concurrently from 30 healthy women aged 64-80 years in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial using chemiluminescent or colorimetric enzyme-linked immune assays. Coefficients of variation (CVs) and correlations were determined.Results: Intraassay CVs ranged from 0.4% for IGFBP-3 to 10% for IGF-II. Mean concentrations of all analytes were higher in the serum, but the differences in mean concentrations of the analytes between serum and plasma were all <11%. Concordance correlation coefficients of matched serum/plasma specimens were 0.92, 0.91, 0.82, 0.96, and 0.99 for IGF-I, IGFBP-3, IGF-II, C-peptide, and leptin, respectively.Conclusion: IGF concentrations measured in serum and plasma are highly correlated but are consistently slightly higher in serum, suggesting that IGF values should be corrected for systematic bias, particularly in consortial efforts when pooling data derived from different specimens.","PeriodicalId":72377,"journal":{"name":"Biomarkers in cancer","volume":"7 ","pages":"13-7"},"PeriodicalIF":0.0,"publicationDate":"2015-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/BIC.S23088","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33413459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Gastrointestinal Stromal Tumors (GIST): A Prospective Analysis and an Update on Biomarkers and Current Treatment Concepts. 胃肠道间质瘤(GIST):生物标志物和当前治疗理念的前瞻性分析和更新。

Biomarkers in cancer Pub Date : 2015-05-21 eCollection Date: 2015-01-01 DOI: 10.4137/BIC.S25045

Anna Koumarianou, Panagiota Economopoulou, Panagiotis Katsaounis, Konstantinos Laschos, Petroula Arapantoni-Dadioti, George Martikos, Athanasios Rogdakis, Nikolaos Tzanakis, Ioannis Boukovinas

引用次数: 17

CD151-A Striking Marker for Cancer Therapy. CD151-A癌症治疗显著标志物

Biomarkers in cancer Pub Date : 2015-03-22 eCollection Date: 2015-01-01 DOI: 10.4137/BIC.S21847

Seema Kumari, Gayatri Devi, Anil Badana, Venkata Ramesh Dasari, Rama Rao Malla

引用次数: 37